The Chemotherapy Foundation

Home
United States
New York, NY
The Chemotherapy Foundation

The Chemotherapy Foundation is dedicated to advancing innovative cancer research at all New York City medical institutions.

We are unique both in our approach and focus.

10/18/2026

What factors contribute to prostate cancer risk? From genetics and lifestyle to environmental exposures, how do these influences shape our understanding of cancer, and how are advances in research transforming the way we detect and treat it?

In this episode of We Speak Cancer, The Chemotherapy+ Foundation welcomes Kai Tsao, MD MS , a member of our Medical Advisory Committee and a leading medical oncologist at Northwell Health Cancer Institute, for a conversation exploring prostate cancer risk factors, the potential impact of environmental exposures, and advancements shaping modern oncology.

The discussion also examines the long-term health concerns associated with September 11, including ongoing research into cancer risks among individuals exposed to environmental hazards at the World Trade Center.

Key Topics & Takeaways:

🔹 Understanding Prostate Cancer Risk: Exploring how age, family history, genetics, and other potential risk factors influence the development of prostate cancer.

🔹Environmental Exposures & Cancer Risk: Examining how environmental factors may contribute to cancer risk, including research into the long-term health effects of exposures associated with 9/11.

🔹Early Detection & Screening: Understanding the role of prostate cancer screening, identifying individual risk, and making informed decisions about when and how to get screened.

🔹Advancements in Prostate Cancer Treatment: How emerging therapies, precision medicine, and more personalized treatment approaches are expanding possibilities for patients.

🔹The Importance of Cancer Research: Why continued scientific investigation is essential to understanding cancer risk, improving detection, and developing more effective therapies.

🔹The Future of Oncology: How evolving research and a deeper understanding of cancer biology are shaping the next generation of cancer care.

Hosted by Paola G. Muggia, Executive Director of TCF, We Speak Cancer is a space to capture, honor, and elevate the real stories of cancer patients. These are the conversations that too often go unheard — full of hope, wisdom, and humanity.

Full episode on our Spotify and YouTube!

10/06/2026

October is

Breast cancer will affect 1 in 8 women in the U.S. during her lifetime, touching countless patients, families, friends, and communities.

At TCF, supporting research that advances our understanding and treatment of breast cancer remains an important part of our mission. We are committed to helping drive progress by supporting innovative research and the physicians and scientists working toward better treatments, better outcomes, and ultimately, a future without breast cancer.

Learn more about our grantees and the groundbreaking work they are leading to advance breast cancer treatments and therapies. Visit our website to explore the research we’re proud to support chemotherapyfoundation.org/our-research/

09/30/2026

Could AI help doctors better understand the risk of breast cancer coming back, even years after treatment?

A new study looked at an AI model that combines several pieces of the puzzle, including patient information, tumor biology, and digital images of the cancer. In this study, the model showed promise in predicting recurrence risk, especially more than five years after diagnosis, in people with early-stage HR-positive, HER2-negative breast cancer.

“Powered by AI integrating clinical, molecular, and histopathology data, this new test provides more reliable prognostic information for breast cancer recurrence,” said lead study author Joseph A. Sparano, MD, a member of our Medical Advisory Council.

The findings are promising, but the tool is not yet a replacement for current tests or treatment guidance. More research is still needed.

At TCF, we’re inspired by research that brings us closer to more personalized cancer care and better answers for patients and families. 💙

Source: The ASCO Post, September 2026

09/20/2026

New research is continuing to shape the future of treatment for advanced and metastatic non-small cell lung cancer (NSCLC).

We are proud to highlight Dr. Roy S. Herbst, a member of our Medical Advisory Council, for his contribution as participating faculty and an author of a comprehensive review examining the evolving role of antibody-drug conjugates (ADCs) in NSCLC.

ADCs represent a more targeted approach to cancer treatment, combining an antibody designed to recognize specific targets on cancer cells with a cancer-killing drug. This approach allows treatment to be directed more precisely toward cancer cells, with the goal of improving effectiveness while limiting effects on healthy tissue.

We are grateful to have leading experts like Dr. Herbst on our Medical Advisory Council, helping TCF remain connected to the research and innovation shaping the future of cancer treatment.

Read the full review from

09/04/2026

September is 🎗️Behind every statistic is a child, a family, and a future worth fighting for.

Today, roughly 87% of children diagnosed with cancer survive at least five years. This is a remarkable improvement from decades past, but progress doesn’t mean the work is finished. Childhood cancer remains the leading cause of death from disease among children and adolescents in the United States.

At TCF, we believe research creates hope. By supporting emerging oncology talent and innovative cancer research, we help advance the discoveries that can lead to better treatments, better outcomes, and more tomorrows.

This month, we stand with every child facing cancer, every family beside them, every survivor, and every researcher working toward what comes next 💛 Together, we can keep progress moving forward.

08/23/2026

Breast cancer screening has evolved significantly, but understanding who is at risk, when to screen, and how emerging technologies may improve detection continues to be an important area of research and discussion.

In this recent episode of We Speak Cancer, Dr. Joseph A. Sparano discusses the changing landscape of breast cancer risk and screening, part of a broader conversation exploring how advances in research and artificial intelligence are helping shape the future of breast cancer detection and care.

Dr. Sparano is a member of The Chemotherapy+ Foundation’s Medical Advisory Council and the Ezra M. Greenspan, M.D. Professor in Clinical Cancer Therapeutics and Chief of the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai. He also serves as Associate Director of Clinical Research Operations at the Mount Sinai Tisch Cancer Center.

Watch the full episode, “Breast Cancer: Risk Factors, Evolution of Screening and A.I. Tools,” to hear more from Dr. Sparano on the progress being made, the questions researchers are still working to answer, and what these advances could mean for the future of breast cancer care.

Full episode available on our YouTube and Spotify channels. Link in bio!

08/17/2026

Today, on , we celebrate the power of people coming together to create meaningful change. At TCF, that means investing in the next generation of oncology innovators and supporting research that advances cancer prevention, treatment, and care.

For nearly 60 years, we have championed collaboration and innovation in the fight against cancer. None of this work happens alone. To our researchers, medical partners, donors, volunteers, board members, and everyone who believes in our mission: thank you for being part of our community!

Help us keep fueling the ideas and emerging talent that can shape the future of cancer care and treatment.

To donate and learn more: chemotherapyfoundation.org

08/10/2026

What if preventing some ovarian cancers could begin with understanding where they start?

Research has changed what we know about ovarian cancer. Evidence suggests that many high-grade serous cancers may actually begin in the fallopian tubes.

For some people, removing the fallopian tubes, a procedure called a salpingectomy, may help reduce ovarian cancer risk while allowing the ovaries to remain in place. But risk is not eliminated, and prevention decisions can look very different depending on personal and family history, genetic risk, age, and reproductive plans.

Swipe through for some important facts about ovarian cancer and fallopian tube removal. Share this information with someone who may benefit from knowing it!

08/03/2026

Treatment for extrapulmonary neuroendocrine carcinoma (epNEC) is entering a new era. While platinum-based chemotherapy remains the current standard of care, researchers are working to develop more personalized approaches that improve outcomes for patients with this rare and aggressive cancer.

Experts in AJMC's The Road Ahead series, including Dr. William Oh, Chairman of The Chemotherapy+ Foundation's Medical Advisory Committee, highlight several promising developments shaping the future of epNEC care:
· Personalized treatment strategies: Researchers are moving toward biomarker-driven care, using a tumor's molecular profile to help guide treatment decisions.
· Combination therapies: Studies are evaluating whether combining chemotherapy with immunotherapy or targeted therapies can produce longer-lasting responses than chemotherapy alone.
· Emerging DLL3-targeted therapies: Novel approaches—including antibody-drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapies, and radiopharmaceuticals—are being investigated for their potential to improve outcomes in epNEC.
· The importance of clinical trials: Continued research is essential to determine which patients benefit most from these emerging therapies and to establish new standards of care.

While many of these approaches are still under investigation, they represent meaningful progress toward more precise, individualized treatment options for patients living with epNEC.

Source: AJMC – The Road Ahead: Personalized Therapy, Combination Approaches, and Key Takeaways in Extrapulmonary Neuroendocrine Carcinoma.

07/30/2026

What we call “ovarian cancer” may often begin somewhere else. Research increasingly shows that many ovarian cancers, particularly high-grade serous cancers, originate in the fallopian tubes. This evolving understanding is changing how researchers and clinicians think about prevention.

It’s a powerful reminder of why cancer research matters. For more than 55 years, TCF has supported emerging oncology talent and innovative research that challenges assumptions and moves promising ideas closer to patient impact.

Science moves forward when we invest in discovery. 🔬💙

Read the full article from The New York Times:
https://www.nytimes.com/2026/07/28/health/ovarian-cancer-fallopian-tubes.html?unlocked_article_code=1.1FA.YOWU.FuPrXE7wVvOG&smid=nytcore-ios-share

Address

New York, NY

Telephone

+12122139292

Website

https://www.chemotherapyfoundation.org/

Alerts

Be the first to know and let us send you an email when The Chemotherapy Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.